Tumor-Naïve Circulating Tumor DNA as an Early Response Biomarker for Patients Treated With Immunotherapy in Early Phase Clinical Trials.
Enrique Sanz-GarciaSofia GentaXiaoxi ChenQiuxiang OuDaniel V AraujoAlbiruni Abdul RazakAaron Richard HansenAnna SpreaficoHua BaoXue WuLillian L SiuPhilippe L BedardPublished in: JCO precision oncology (2023)
A decrease in ctDNA within 4 weeks of treatment was associated with treatment outcomes in patients in early phase IO trials. Tumor-naïve ctDNA assays may be useful for identifying early treatment benefits in phase I/II IO trials.